EVOLUS INC (EOLS)
Health Care · Medical Aesthetics · NASDAQ
A growth-oriented aesthetic beauty company disrupting the injectable market with a customer-centric, cash-pay model for neurotoxins and dermal fillers.
What EVOLUS INC does
Evolus is a global performance beauty company that focuses on the cash-pay aesthetic market. The company develops and markets injectable aesthetic products, including botulinum toxin type A and a portfolio of hyaluronic acid (HA) dermal fillers for facial rejuvenation and skin quality.
Recent developments
Raised 2026 revenue guidance following strong Q2 results and three consecutive quarters of positive Adjusted EBITDA. Secured exclusive US commercialization rights for Profhilo (launch anticipated 2030) and expanded international rights for the Estyme HA portfolio.
From EVOLUS INC's filing of 2026-08-05.
Themes: Medical Aesthetics, Injectable Neurotoxins, Dermal Fillers, Beauty / Anti-aging, Cash-pay healthcare, Digital commercial platform
Fundamentals
- Price$7.40 as of 2026-10-21 close
- Market cap$489M as of 2026-07-31 (share count; price 2026-10-21)
- 1-year return+9.0% 2025-10-21 close $6.79 → 2026-10-21 close $7.40
- P/En/a negative earnings
- Net margin-17.4% FY2025, SEC XBRL
- Gross margin+66.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its stockholders' equity is zero or negative, where the ratio means nothing.
- Revenue growth (YoY)+11.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+26.0% SEC XBRL
- Beta1.27 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How EOLS compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $84M | $57M | -$5M | -$8M | -$0.12 | -$4M† | $50000† |
| Q1 FY2026 2026-03-31 | $73M | $49M | -$7M | -$11M | -$0.16 | -$10M | $415000 |
| Q4 FY2025 2025-12-31 | $90M† | $59M† | $4M† | $130000† | $0.00† | $13M† | $1M† |
| Q3 FY2025 2025-09-30 | $69M | $46M | -$12M | -$16M | -$0.24 | -$15M† | $955000† |
| Q2 FY2025 2025-06-30 | $69M | $45M | -$10M | -$17M | -$0.27 | -$25M† | $688000† |
| Q1 FY2025 2025-03-31 | $69M | $47M | -$15M | -$19M | -$0.30 | -$16M | $319000 |
| Q4 FY2024 2024-12-31 | $79M† | $53M† | -$2M† | -$7M† | -$0.10† | $5M† | $438000† |
| Q3 FY2024 2024-09-30 | $61M | $42M | -$15M | -$19M | -$0.30 | -$6M† | $313000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$45M
- Total debt$157M borrowings only; leases excluded
- Net debt$112M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How EVOLUS INC looks technically
EVOLUS INC (EOLS) is trading 19.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 84 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago. It is 20.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 19.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.09 | $8.09 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.20 | $6.20 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 7.83. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 84 trading days ago — a "golden cross", a bullish long-term signal | 84 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.7 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($6.91 to $7.83) — its "stochastic" reading is 53 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 53.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 32 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.31 | $9.31 |
|---|---|---|
| From the 52-week high | it is 20.5% below its 52-week high (its highest price of the past year) | -20.5% |
| Above the 52-week low | it is 91.7% above its 52-week low (its lowest price of the past year) | +91.7% |
| Below the 52-week high | it is 20.5% below its highest point of the past year | 20.5% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $39.50 (set on 2018-06-07) | $39.50 |
| Given back of the 52-week move | over the past year its closes ranged ($3.94 to $9.30), and it has given back roughly a third of its rise from last year’s low — 35% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.82 to $5.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 35.5% |
| From the all-time high | it is 81.3% below its all-time high | -81.3% |
| Nearest price level | it is trading 0.7% above a support level at $7.35 — a price it turned at three times since 2025-10-29, most recently on 2026-06-26. Since 2024-10-21 it has 9 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.7% |
| All-time low | its lowest closing price on record is $2.85 (set on 2020-10-29) | $2.85 |
| Above the all-time low | it is 159.6% above its all-time low | +159.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 81% of it) | 19th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3495 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3495 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.04 and $8.16 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.04 – $7.60 – $8.16 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (19.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.22× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 3.2% below the previous close 31 sessions ago and has not traded back through the level it left behind at 9.3 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.2% |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +4.23% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.3 percentage points (the stock lost 7.4% while the market lost 0.1%) | -7.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 24.2 percentage points (the stock gained 27.5% while the market gained 3.3%) | +24.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 40.3 percentage points (the stock gained 50.1% while the market gained 9.8%) | +40.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 6.2 percentage points (the stock gained 9.0% while the market gained 15.2%) | -6.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 13.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $6.17 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | +20.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.04 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | -8.0% |
Price levels it has turned at before
EOLS last closed at $7.40 on 2026-10-21. Since 2024-10-21 it has turned at 9 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.35 | Support | 0.7% below the last close | turned there three times · 2025-10-29 to 2026-06-26 |
| $7.19 | Support | 2.8% below the last close | turned there three times · 2025-09-03 to 2026-07-08 |
| $7.78 | Resistance | 5.1% above the last close | turned there three times · 2025-09-05 to 2026-10-12 |
| $6.76 | Support | 8.7% below the last close | turned there twice · 2026-05-18 to 2026-05-28 |
| $8.47 | Resistance | 14.5% above the last close | turned there twice · 2026-08-11 to 2026-09-23 |
| $8.71 | Resistance | 17.7% above the last close | turned there twice · 2025-04-09 to 2025-05-28 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $7.83.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $5.25 and $6.23 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $7.83.
This reading has stood for 3 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · beating the market · Printed a bullish engulfing pair · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$15.00 range $12.00 – $20.00; median $13.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EOLS
- Consensus EPS estimate-$0.0675 next reporting period, as of 2026-10-15
- Estimate change, 30 days-$0.0075 from -$0.06, on 2026-09-10, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and potential need for additional capital.","Dependence on third-party manufacturers (Daewoong and Symatese) for core product supply.","Exposure to potential import tariffs and trade policy volatility impacting costs and margins."]
What changed in the latest 10-Q
AI-assisted comparison of EOLS's 10-Q filed 2026-08-05 against the prior one filed 2026-05-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) describes under 'Recent Key Developments' entering into a License, Supply and Distribution Agreement (IBSA Agreement) with IBSA Institut Biochimique SA on July 7, 2026, granting exclusive U.S. rights to develop, commercialize and distribute Profhilo for aesthetics/dermatological fields, with no upfront or milestone payments, and anticipated U.S. commercialization in 2030 subject to regulatory approval.
- Newer filing (2026-08-05) describes under 'Recent Key Developments' entering a series of agreements with Symatese on August 3, 2026 that amended and expanded commercialization rights, adding exclusive rights to commercialize the full Evolysse injectable HA gel line in Europe and new territories of Canada, Australia and New Zealand, with aggregate upfront payments of €1.4 million and potential additional payments up to €2.9 million upon regulatory approvals/registrations, and anticipated commercialization in these new territories in 2028 subject to regulatory approvals.
- Newer filing (2026-08-05) in 'Market Trends and Uncertainties' states that during the second quarter of 2026 Evolysse, imported from the European Union, was subject to a temporary 10% tariff, and on July 24, 2026 those tariffs expired and were replaced by a new 10% tariff on Evolysse under Section 301 of the Trade Act of 1974.
- Newer filing (2026-08-05) in 'Market Trends and Uncertainties' states that beginning September 29, 2026, Jeuveau, manufactured in South Korea, could be subject to a 15% tariff under Section 232 of the Trade Expansion Act of 1962 depending on how applicable rules are interpreted, and that the company has increased inventory purchases in advance of the potential Jeuveau tariff and is evaluating other mitigation measures.
- Newer filing (2026-08-05) provides results of operations for the three months ended June 30, 2026 and 2025, including specific figures: product revenue net $83,350 vs $68,699; service revenue $734 vs $688; total net revenues $84,084 vs $69,387; cost of goods sold $26,904 vs $24,067; gross profit $57,180 vs $45,320; gross profit margin 68.0% vs 65.3%; selling, general and administrative $57,052 vs $56,675; research and development $1,892 vs $1,837; revaluation of contingent royalty obligation payable to Evolus Founders $1,250 vs $(3,914); depreciation and amortization $1,529 vs $932; total operating expenses $61,723 vs $55,530; loss from operations $(4,543) vs $(10,210); interest expense net $(3,876) vs $(6,728); other income (expense) net $213 vs $(151); loss before income taxes $(8,206) vs $(17,089); income tax benefit (expense) $154 vs $(53); net loss $(8,052) vs $(17,142); currency translation adjustment $(251) vs $240; comprehensive loss $(8,303) vs $(16,902).
- Removed:
- Older filing (2026-05-04) in 'Overview' states that in April 2025 the company launched Evolysse Form and Evolysse Smooth in the United States, indicated for wrinkles and folds such as nasolabial folds in adults, and that the company expected to launch all four Evolysse products in Europe in the second quarter of 2026.
- Older filing (2026-05-04) in 'Recent Key Developments' describes entering into a Loan and Security Agreement with Eclipse Business Capital LLC on March 3, 2026, providing a $30.0 million senior secured asset-based revolving credit facility with an uncommitted accordion feature of up to $10.0 million, maturing March 3, 2029, minimum utilization of $10.0 million, interest at adjusted term SOFR (floor 2.0%) plus 4.25%, secured by substantially all assets and guaranteed by the company and subsidiaries.
- Older filing (2026-05-04) in 'Market Trends and Uncertainties' states that on April 2, 2026, the White House issued a proclamation addressing imports of patented pharmaceuticals, authorizing tariffs on certain imports including from countries such as South Korea, and that as Jeuveau is manufactured and imported from South Korea, these measures may apply to Jeuveau, though scope, timing and applicability remain uncertain.
- Older filing (2026-05-04) provides results of operations for the three months ended March 31, 2026 and 2025, including specific figures: product revenue net $72,747 vs $68,074; service revenue $390 vs $448; total net revenues $73,137 vs $68,522; cost of goods sold $24,240 vs $21,867; gross profit $48,897 vs $46,655; gross profit margin 66.9% vs 68.1%; selling, general and administrative $51,981 vs $56,640; research and development $2,240 vs $2,212; revaluation of contingent royalty obligation payable to Evolus Founders $(14) vs $2,151; depreciation and amortization $1,538 vs $824; total operating expenses $55,745 vs $61,827; loss from operations $(6,848) vs $(15,172).
- Reworded:
- The 'Market Trends and Uncertainties' section in the newer filing (2026-08-05) was reorganized and condensed compared to the older filing (2026-05-04), with the newer text consolidating macroeconomic observations into a single paragraph and moving tariff-related details into product-specific tariff discussions.
- The newer filing (2026-08-05) replaced the opening Evolysse launch detail in the 'Overview' section with a statement only noting current sale of Evolysse Form and Evolysse Smooth in the U.S. and four Evolysse products in Europe, removing the April 2025 U.S. launch date, indications, and expected Q2 2026 European launch timing present in the older filing (2026-05-04).
- The newer filing (2026-08-05) moved the 'Recent Key Developments' section to appear before 'Market Trends and Uncertainties', whereas the older filing (2026-05-04) placed 'Market Trends and Uncertainties' before 'Recent Key Developments'.
- The newer filing (2026-08-05) in 'Market Trends and Uncertainties' revised the description of U.S. macroeconomic conditions to state conditions 'remain mixed and uncertain, with moderating inflation and continued economic expansion offset by muted job growth, weaker consumer confidence, and evolving tariff and trade policy developments', replacing the older filing's framing that inflation 'is moderating', job growth 'has been muted', and consumer confidence 'has generally been weakening'.
- The newer filing (2026-08-05) expanded the IEEPA tariff refund discussion to state the company 'submitted claims for refunds of certain tariffs previously paid' and that 'the amount and timing of any refunds remain uncertain', whereas the older filing (2026-05-04) only stated the company was 'pursuing potential refunds of previously paid IEEPA tariffs'.
- The newer filing (2026-08-05) changed the interest rate risk disclosure date reference from 'As of March 31, 2026' to 'As of June 30, 2026'.
- Notes:
- The newer filing text is truncated at 'Net Revenues / We currently operate one reportable segment, and our net product revenues are derived from the sale of Jeuveau ® and Evolyss', so changes after that point could not be assessed.
- The older filing text is truncated at 'Interest e' in the results of operations section, so some figures or narrative in the older filing may be incomplete.
- The newer filing only contains Q2 2026 (three months ended June 30, 2026) financial data while the older filing contains Q1 2026 (three months ended March 31, 2026) financial data; these are different reporting periods and are not directly comparable as an addition-versus-removal of the same table.
Risk Factors
- Added:
- In the filing dated 2026-08-05, the recorded net loss for the six months ended June 30, 2026 is stated as $18.7 million.
- In the filing dated 2026-08-05, the accumulated deficit as of June 30, 2026 is stated as $679.8 million.
- Removed:
- In the filing dated 2026-05-04, the recorded net loss for the three months ended March 31, 2026 is stated as $10.7 million.
- In the filing dated 2026-05-04, the accumulated deficit as of March 31, 2026 is stated as $671.7 million.
- Reworded:
- In the filing dated 2026-08-05, the spacing around the quotation mark in 'Item 2“Management’s...' changed to 'Item 2 “Management’s...' (a space was added after '2').
- Notes:
- Both supplied texts are truncated at the same point in the section, so changes after the truncation point cannot be assessed.
- No other differences were detected between the two provided excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 90 days · read to 2026-10-170 buys · 1 sell ($950019) — 1 selling insider
- Last 180 days · read to 2026-10-170 buys · 1 sell ($950019) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-02. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EOLS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding EOLS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,887,504
- Reported value $54,739,282
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about EOLS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
EOLS had 5,628,168 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
EOLS had 8.52% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.33 days to cover at the same settlement.
- Reported short interest (shares) 5,628,168
- Short interest (% of shares outstanding) 8.52%
- Prior settlement (shares) 5,530,759
- Reported change 1.76%
- Days to cover (reported) 9.33
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV) (BOTOX / JUVÉDERM)
- Galderma (Dysport / Restylane)
- Revance Therapeutics (RVNC) (DAXXIFY)
- Merz Aesthetics (Xeomin / Belotero)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EOLS vs…
Frequently asked questions
What does EVOLUS INC (EOLS) do?
Evolus is a global performance beauty company that focuses on the cash-pay aesthetic market. The company develops and markets injectable aesthetic products, including botulinum toxin type A and a portfolio of hyaluronic acid (HA) dermal fillers for facial rejuvenation and skin quality.
What sector is EVOLUS INC (EOLS) in?
EVOLUS INC (EOLS) is classified in the Health Care sector. Its industry is Medical Aesthetics. It trades on NASDAQ.
Who are EVOLUS INC's (EOLS) competitors?
Notable peers of EVOLUS INC (EOLS) include AbbVie (ABBV) (BOTOX / JUVÉDERM), Galderma (Dysport / Restylane), Revance Therapeutics (RVNC) and Merz Aesthetics (Xeomin / Belotero). This peer set is informational only — not financial advice.
Is EVOLUS INC (EOLS) overbought or oversold right now?
EVOLUS INC (EOLS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EOLS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.